Arimidex Study Group. Buzdar AU, Jonat W, Howell A, et al. Arimidex Study Group. Dombernowsky P, Smith I, Falkson G, et al. J Clin Oncol .
More research is needed regarding hormonal therapy resistance.
This should be the era to look for new molecular markers that predict response, but such markers have not yet been identified. I think it's fascinating that until two years ago, we blithely assumed that there was only one estrogen receptor. It would be interesting to know because tamoxifen and receptors were the first cases of targeted therapies in breast cancer or in any cancer. It would be wonderful if we could target them even better. The randomized data have suggested improved response rates with oophorectomy first-line for premenopausal women with metastatic disease.